OPTN News and Press, OptiNose Inc. From 08/13/22

OptiNose, Inc. (OPTN) Q2 2022 Earnings Conference Call August 11, 2022 08:00 AM ET Company Participants Jonathan Neely - IR Peter Miller - CEO Ramy Mahmoud - President and COO Vic Clavelli - Chief Commercial Officer Conference Call Participants Br...

OptiNose press release ( NASDAQ: OPTN ): Q2 GAAP EPS of -$0.23 beats by $0.01 . Revenue of $20.6M (+12.0% Y/Y) misses by $0.9M . For further details see: OptiNose GAAP EPS of -$0.23 beats by $0.01, revenue of $20.6M misses by $0.9M

Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second quarter 2021 Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis by the end of 2022 Company expects full year 2022 XHANCE net revenue t...

YARDLEY, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2022 and corporate updates...

XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trials to reduce exacerbations for patients with chronic sinusitis Pre-planned analysis of pooled data from the landmark ReOpen trials reveals 66% reduction in sinusitis exacerbations (flares) wit...

Optinose ( NASDAQ: OPTN ) said a pooled analysis of two Phase 3 trials showed that its nasal spray Xhance showed benefit over placebo in patients with chronic sinusitis. The company had previously reported data from the studies, ReOpen1 and ReOpen2 , a...

Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis Multiple secondary endpoints from ReOpen2 indicate patients treated with XHANCE experienced improvement in symptoms an...

OptiNose's revenue was $14.8 million in the first quarter, up 23.3% year-over-year. The company has published the results of two Phase 3 clinical trials that met both primary and secondary endpoints. Xhance may receive approval for chronic sinusitis in 2023, which would increase t...

The June Federal Reserve meeting has concluded, and the stock market has responded. Investors and traders alike have begun positioning themselves based on the latest commentary from Jerome Powell’s FOMC press conference. The interesting part about this is that some stocks don’...

Gainers: Day One Biopharmaceuticals (DAWN) +103%. Redbox Entertainment (RDBXW) +85%. OptiNose (OPTN) +37%. Cerberus Cyber Sentinel Corporation (CISO) +36%. Ekso Bionics Holdings (EKSO) +35%. AeroClean Technologies (AERC) +33%. Redbox Entertainment (RDBX) +29%. Electro-Sensors (ELSE) +17%. Cyn...